Provided by Tiger Fintech (Singapore) Pte. Ltd.

Incyte

87.30
+1.131.31%
Post-market: 88.401.10+1.26%18:10 EDT
Volume:1.14M
Turnover:98.91M
Market Cap:17.05B
PE:19.99
High:87.48
Open:85.65
Low:85.55
Close:86.17
52wk High:92.86
52wk Low:53.56
Shares:195.28M
Float Shares:163.04M
Volume Ratio:0.50
T/O Rate:0.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):4.37
EPS(LYR):0.1575
ROE:24.30%
ROA:11.52%
PB:4.09
PE(LYR):554.37

Loading ...

Incyte price target raised to $81 from $72 at RBC Capital

TIPRANKS
·
Sep 24

Incyte (INCY) Gets a Hold from RBC Capital

TIPRANKS
·
Sep 24

Incyte : RBC Raises Target Price to $81 From $72

THOMSON REUTERS
·
Sep 24

RBC Raises Price Target on Incyte to $81 From $72, Keeps Sector Perform Rating

MT Newswires Live
·
Sep 24

Incyte Corp. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Sep 23

Incyte appoints Dave Gardner chief strategy officer

TIPRANKS
·
Sep 22

Incyte Corporation Appoints Dave Gardner as Executive Vice President and Chief Strategy Officer Amid Leadership Transition

Reuters
·
Sep 22

Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer

THOMSON REUTERS
·
Sep 22

Incyte price target raised to $115 from $110 at Stifel

TIPRANKS
·
Sep 22

Guggenheim Keeps Their Hold Rating on Incyte (INCY)

TIPRANKS
·
Sep 19

Jefferies Adjusts Price Target on Incyte to $102 From $90, Maintains Buy Rating

MT Newswires Live
·
Sep 19

Incyte’s Growth Potential Boosted by Opzelura Approval and Strategic Focus on Myeloproliferative Neoplasms

TIPRANKS
·
Sep 19

Incyte : Jefferies Raises Target Price to $102 From $90

THOMSON REUTERS
·
Sep 19

Top Incyte Executive Offloads Company Shares in Lucrative Sale

TIPRANKS
·
Sep 19

Incyte Gets FDA Approval for Dermatitis Cream for Young Children

Dow Jones
·
Sep 19

Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 With Atopic Dermatitis

THOMSON REUTERS
·
Sep 19

Incyte’s Povorcitinib Shows Promise but Faces Competitive Challenges: Hold Rating Maintained

TIPRANKS
·
Sep 18

Barclays Keeps Their Buy Rating on Incyte (INCY)

TIPRANKS
·
Sep 18

TD Cowen Sticks to Their Buy Rating for Incyte (INCY)

TIPRANKS
·
Sep 18

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Sep 18